You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. ARCHER- An Extremely Fast Medical Radiation Dose Computing Software

    SBC: VIRTUAL PHANTOMS INC            Topic: NIBIB

    DESCRIPTIONprovided by applicantThe goal of this project is to develop a commercial software package for rapid Monte Carlo based dose computation in imaging and radiation therapyThe product takes advantage of a desktop parallel computer equipped with emerging hardware originally developed gaming and high performance computingThe project is motivated by the fact that the market is ripe for a produc ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Pre Clinical Safety and Efficacy of TRB N for the Treatment of Periodontal Disease

    SBC: TRAVERSE BIOSCIENCES, INC.            Topic: NIDCR

    PROJECT SUMMARY ABSTRACT Traverse Biosciences Inc is a pre clinical stage drug development company working to commercialize new chemical entities which act to resolve inflammatory conditions through pleiotropic host modulation of pathologically unrestrained matrix metalloproteinases MMPs and pro inflammatory cytokines The companyandapos s lead drug candidate TRB N is a proprietary chemic ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Development and validation of therapy for mucopolysaccharidosis III

    SBC: Phoenix Nest Inc.            Topic: 105

    DESCRIPTION provided by applicant Sanfilippo syndrome mucopolysaccharidosis type III MPS III is a devastating neurodegenerative lysosomal storage disorder of childhood for which there is presently no cure or effective treatment available The fundamental cause of MPS III is an inherited mutation in one of the enzymes required to catabolize heparan sulfate HS a glycosaminoglycan which pla ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Image guided Planning System for Skull Correction in Children with Craniosynostosis Phase II

    SBC: Kitware, Inc.            Topic: NICHD

    DESCRIPTION provided by applicant Craniosynostosis is the premature fusion of cranial sutures and occurs in approximately one in live births It results in cranial malformation that can lead to elevated intra cranial pressure brain growth impairment and developmental deficiency The most common treatment option for craniosynostosis is surgery Currently surgical treatment planning of c ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Mutation Enriched Targeted Re Sequencing

    SBC: TRANSGENOMIC, INC.            Topic: 103

    DESCRIPTION provided by applicant Low level tumor associated somatic DNA mutations can have profound implications for development of metastasis prognosis choice of treatment follow up or early cancer detection Unless they are effectively detected these low level mutations can misinform patient management decisions or become missed opportunities for personalized medicine Widely used tech ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government